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Abstract 
Objective: Pilot trial comparing prism therapy and visual search training, for homonymous hemianopia, to standard care 
(information only). 
Methods: Prospective, multicentre, parallel, single-blind, three-arm RCT across fifteen UK acute stroke units. 
Participants: Stroke survivors with homonymous hemianopia. 
Interventions: Arm a (Fresnel prisms) for minimum 2 hours, 5 days/week over 6-weeks. Arm b (visual search training) for minimum 
30 minutes, 5 days/week over 6-weeks. Arm c (standard care-information only).  
Inclusion criteria: Adult stroke survivors (>18 years), stable hemianopia, visual acuity better than 0.5logMAR, refractive error within 
±5Dioptres, ability to read/understand English, and provide consent.  
Outcomes: Primary outcomes were change in visual field area from baseline to 26 weeks and calculation of sample size for a 
definitive trial. Secondary measures included Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham 
Extended Activities of Daily Living, Euro Qual, Short Form-12 questionnaires and Radner reading ability. Measures were post-
randomisation at baseline and 6, 12, 26 weeks. 
Randomisation: Randomisation block lists stratified by site and partial/complete hemianopia. 
Blinding: Allocations disclosed to patients. Primary outcome assessor blind to treatment allocation. 
Results: 87 patients were recruited: 27 - Fresnel prisms, 30 – visual search training and 30 - standard care. 69% male; mean age 
69 years (SD 12). At 26 weeks, full results for 24, 24 and 22 patients respectively were compared to baseline. Sample size 
calculation for a definitive trial determined as 269 participants per arm for a 200 degree2 visual field area change at 90% power. 
Non-significant relative change in area of visual field was 5%, 8% and 3.5% respectively for the three groups. Visual Function 
Questionnaire responses improved significantly from baseline to 26 weeks with visual search training (60 (SD19) to 68.4 (SD20)) 
compared to Fresnel prisms (68.5 (SD16.4) to 68.2 (18.4): 7% difference) and standard care (63.7 (SD19.4) to 59.8 (SD22.7): 10% 
difference), p=0.05. Related adverse events were common with Fresnel prisms (69.2%; typically headaches).  
Conclusions: No significant change occurred for area of visual field area across arms over follow-up. Visual search training had 
significant improvement in vision-related quality of life. Prism therapy produced adverse events in 69%. Visual search training 
results warrant further investigation.  
The trial is funded by the UK Stroke Association. Trial Registration: Current Controlled Trials ISRCTN05956042. 
 
Keywords: Homonymous hemianopia; Pilot trial;  Prism therapy; Randomised controlled trial; Standard care; Stroke; Visual search 
training 
 
  
Introduction 
Homonymous hemianopia results in loss of one half of the visual field in both eyes [1,2]. The reported prevalence of visual field loss 
following stroke has been as high as 63% [3] in hospital populations although estimates vary widely as the proportion testing 
positive is highly dependent on time post stroke. Visual field defects can seriously impact functional ability and quality of life 
following stroke [4,5]. Patients with visual field defects have an increased risk of falling [6], impaired ability to read, poor mood and 
institutionalization [6-9]. Visual field loss may impact on a patient`s ability to participate in rehabilitation, and may ultimately result in 
poor long term recovery [8]. Visual field loss can result in accidents or injuries which have subsequent cost implications to the NHS 
and the patient [10]. 
Two key interventions commonly used in the clinical setting to improve vision in hemianopia are visual search compensatory 
training and provision of prisms [11]. A Cochrane systematic review [11] evaluated the interventions for homonymous hemianopia 
and found evidence in favour of visual search training. Subsequently, Aimola and colleagues [12] conducted a trial of visual search 
training for homonymous hemianopia and reported evidence of improved quality of life in the intervention group. The Cochrane 
review did not find sufficient evidence for prisms as an intervention for hemianopia.  
The aim of this pilot trial was to to compare  visual rehabilitation interventions with NHS standard care, in patients with hemianopia 
following stroke. We wished to explore whether visual rehabilitation was more effective than standard care (advice only) at 
improving functional outcome in patients with hemianopia following stroke, and whether prism therapy or visual search therapy was 
more effective at improving functional outcome in patients with hemianopia following stroke. 
 
Methods 
Trial design 
VISION was a randomised controlled, multicentre pilot trial with NHS research ethical approval (10/H1003/119). The trial protocol is 
reported elsewhere [13].  
Participants 
Patients were eligible for inclusion if they met the criteria: 
a. 18 years of age or older; 
b. Best corrected visual acuity of 0.5 or better in each eye at distance; 
c. Stable homonymous hemianopia (partial or complete) induced by recent stroke, defined following WHO guidelines, present over 
2 weeks (to exclude rapid recovery cases) but less than 26 weeks prior to randomisation;  
d. Refractive error within ±5Dioptres; 
e. Willing and able to give consent for the study; 
f. Prior to stroke able to read and understand English. 
 Patients were not eligible for inclusion if they were: 
a. unable to consent due to severe cognitive impairment; 
b. assessed to have ocular motility impairment and/or visual inattention in addition to the visual field impairment; or 
c. had pre-existent visual field impairment due to previous stroke. 
 
Participants were recruited from stroke units based in 15 United Kingdom (UK) National Health Service (NHS) Trusts.  Potentially 
eligible participants were identified by stroke research nurses, and screened for inclusion by a local principal investigator (a 
qualified orthoptist registered with the health and Care Professions Council, UK). Participants eligible for inclusion, and providing 
consent, attended for a baseline assessment, which included assessment and documentation of patient demographics, visual signs 
and symptoms, visual acuity measures, any additional ocular problems, comorbidity, severity of stroke and level of disability.   
 
Recruitment and randomisation 
Participants were individually randomised to one of three treatment groups using a secure (24-hour) web based randomisation 
programme. Randomisation lists were generated using block randomisation stratified by centre and degree of hemianopia (partial 
or complete) with treatment allocation ratio of 1:1:1. The local PI (orthoptist) obtained the treatment allocation and subsequently 
assigned the participant to the treatment arm. 
 
Interventions 
Treatment A: Fresnel prisms 
Participants were assessed and given sector Fresnel prisms of 40 prism dioptre strength on their glasses (or plain glasses if not 
already worn) [14]. Separate prism segments were used as a mechanical displacement to expand the upper and lower quadrants. 
Full fitting details are detailed in the protocol [13]. Participants were advised to wear the prisms for a minimum of 2 hours daily, for a 
minimum six weeks, from prism affixation; after this they could elect to continue treatment if wished.  
Treatment B: Visual search training 
Participants were assessed and provided with visual search training. This comprised an A4 landscape card with horizontal and 
diagonal numbered circles radiating out from a central fixation target. Full instructions for training are detailed in the protocol [13]. 
Participants were instructed to continually scan between the various targets for 30 minutes daily for a minimum six weeks, after 
which they could elect to continue treatment if they wished. Participants were instructed on the search exercises to ensure their 
understanding of doing this training. In addition, printed instructions were provided with the visual training target cards.  
Treatment C: Control - Standard Care (Information Only) 
Participants were given information leaflets from the UK Stroke Association and the UK Royal National Institute for the Blind (RNIB) 
about visual impairment following stroke.  
 
Participants in all treatment groups received these information leaflets. Details of usage of the prisms and visual search training 
were collected by diaries, completed daily by participants.  
 
Outcomes 
Outcomes were assessed at baseline, 6, 12 and 26 weeks. The primary clinical outcome was relative change in visual field area 
(measured in degrees2) from baseline to 26 weeks and, based on this change, a sample size calculation for a future definitive trial. 
Secondary clinical outcomes, assessed by the orthoptist, were reading ability (speed and accuracy). Secondary clinical outcomes, 
reported by patients, were assessed through questionnaire booklets. [13].  Further key objectives of this pilot trial were to test the 
operationalisation of the intervention and the study outcome measures [13, 15].   
 
Sample size calculation 
A sample size calculation was estimated for repeated measures analysis of covariance [16], using the data generated on visual 
field assessment.  
 Visual field assessment 
A blinded qualified Orthoptist assessed visual field area. An Esterman strategy was used for quantitative visual field assessment 
with standard fixation monitoring strategies of fixation loss, false positive and false negative responses. This was done using either: 
 The Esterman programme on Humphrey or Octopus perimetry, 
 The III4e target on Goldmann with additional checks of static points in the central visual field. 
A template for Goldmann perimetry was supplied for standardisation to match the Esterman strategy on Humphrey and Octopus 
perimetry. A binocular visual field was measured first followed by monocular assessment of the right and left eyes. Visual fields 
were performed without prisms in place in the Fresnel prism arm. Where it was not possible to use either of these methods then the 
standardised confrontation method was used. Whichever method used at baseline was repeated at every follow up visit. Where the 
confrontation method was used at baseline one of the above quantitative methods was used at the follow-up if possible in addition 
to repeating the confrontation method. 
 
Reading Ability 
Reading ability, assessed using the Radner reading test, is reported as time taken to read (seconds) and number of incorrect words 
from the 14 word passage [17]. 
 Patient Completed Outcome Measures 
Participants completed a questionnaire booklet containing the following outcome measures: 
a. Visual function questionnaire (VFQ 25-10) [18] 
b. Rivermead mobility index (RMI) [19] 
c. Nottingham extended activities of daily living assessment (NEADL) [20] 
d. Euro Qual [21] 
i. 5D (EQ-5D) 
ii. VAS score (EQ-VAS) 
e. Short Form -12 (SF-12) [22] 
 i. Physical component summary (PCS) 
 ii. Mental component summary (MCS) 
 
 
Statistical Analysis 
There were insufficient data to carry out a formal power calculation to determine sample size for this trial, a sample size of 105 
participants was considered sufficient to reach pilot objectives [13].  
 
Outcome data were analysed according to the intention-to-treat principle. Safety analyses included all patients were randomised to 
and received treatment. A p-value of 0.05 is considered significant, however as this is a pilot study not powered to identify 
differences, results will be interpreted with caution. Additionally, rather than adjust for multiplicity relevant results from other studies 
will be taken into account in the interpretation of results.  
 
The statistical analysis plan, written by the trial statisticians and agreed by other members of the trial management group (TMG) 
and independent oversight committees: data and safety monitoring committee (IDSMC) and the trial steering committee (TSC), 
prior to any comparative analyses together is available on request from the authors. No imputation methods were used for missing 
data and all patients who withdrew from the trial were encouraged to complete follow up. 
 
All analyses were done with SAS software version 9.2. The primary feasibility outcome of sample size calculation was calculated 
for a repeated measures analysis of covariance [16]. Data collected from the trial were used to estimate the standard deviation, 
estimate of correlation and the loss to follow up rate for the main trial. All outcomes were summarised using descriptive statistics, 
split by treatment, at baseline and 26 week follow up. The primary efficacy outcome was relative change in area of visual field 
assessment (VFA), defined as the difference in VFA from baseline to 26 weeks follow up, divided by the maximum possible VFA 
score for each method, and was analysed using ANOVA, controlling for treatment. A sensitivity analysis was performed on the VFA 
using ANCOVA for the modal assessment method (see Outcomes – Visual Field Assessment). Patient reported secondary 
outcomes: VFQ 25-10; RMI; NEADL; EQ-VAS and SF-12: PCS and MCS, reported at 26 week follow up, were compared using 
analysis of covariance, controlling for treatment and baseline assessment. EQ-5D and Radner Reading Score were summarised 
using only descriptive statistics,   
 
 
Results 
Recruitment and characteristics 
Recruitment and screening have been reported elsewhere [23). In summary, 1171 patients were assessed for eligibility between 
17th May 2011 and 9th September 2013. Of these, 993 patients (84.8%) did not meet the inclusion criteria, 91 patients declined to 
participate (7.8%) leaving 87 patients in the study (7.4%). The reasons for not being eligible and for refusing to consent were 
recorded and published [23]. 
In May 2012, the team noted that the proportion of eligible patients was lower than expected and this was slowing recruitment. 
Upon reviewing the accumulating recruitment data, the IDSMC recommended extending recruitment by one year and advised that 
the initial target sample size of 105 be reduced to 90 participants, of which 60 would be needed to complete the study. The TSC 
agreed with this proposal and the TMG actioned this amendment in June 2012. Figure 1 shows the cumulative recruitment graph, 
indicating expected, revised expected and actual recruitment by month.  
At the end of the recruitment period, 27, 30 and 30 patients were randomised to Fresnel prisms, Visual search training and 
standard care respectively. Two  patients (2/87, 2.3%) withdrew from data analysis and follow up; nine (9/87, 10.3%) from follow up 
only and  five (5/87, 5.7%) were lost to follow up, of which four were from the standard arm (4/5, 80.0%). There was 24 (24/27, 
88.9%), 25 (25/30, 83.3%) and 22 (22/30, 73.3%) patients in the Fresnel prisms, Visual search training and standard care 
respectively at 26 week follow up (see Figure 2).  
Patient demographic and clinical characteristics at baseline are provided in Table 1 and 2. There were no notable differences at 
baseline between three arms. The population consisted primarily of white (97.6%) males (69.4%) randomised, on average, 11 
weeks post ischaemic (95.3%) stroke (late recruitment relating to the requirement for stable, non-recovering hemianopia). The 
infarct was mostly classified unilateral (43.5% left; 54.1% right).  
 
Sample size outcome 
Table 3 provides the sample size needed per arm to detect a minimally clinically important difference in visual field between per 
arm for a given power. Predictions are provided for three values of the minimally clinically important difference (200, 400 and 600 
degrees2) and for three levels of power (90%, 80% and 50%). 80% (70/87) of patients had full data at baseline and 26 weeks. Thus 
the required number of patients to be recruited was calculated as 1.25 times (=1/0.8) the sample size shown in Table 3. Most 
recruiting sites used the Humphrey Static methods, with 33 in 70 (47.1%) patients having their VFA assessed using this method. 
Computing the sample size in the same way for patients being assessed by this method only reduces the number required (Table 
3). 
 
Primary clinical outcome 
There was some variability in baseline relative change in visual field area across treatment arm and by method (Table 4), 
particularly those methods used most frequently. For the Humphrey Static Esterman method, the mean baseline visual field area 
was one-third lower in the standard care arm (955.8 degrees) when compared to the visual search training or Fresnel prism arm; 
1428.9 degrees and 1382.5 degrees respectively. For the Octopus Static Esterman method, the mean baseline visual field was 
44.2% and 18.4% higher in the standard care arm when compared to the visual search training and Fresnel prism arm respectively. 
These differences can be explained by the large within-group variances of visual field  expected with a relatively low sample size 
per method of assessment and per arm. 
The mean values of relative change in visual field area are given in Table 5, which shows a non-significant average minimal 
increase in visual field at 26 weeks of 5%, 8% and 3.5% for Fresnel prisms, Visual search training and standard care, respectively 
(p-values >5%, <5% and >5%, respectively).  
 
Secondary clinical outcomes 
Change in functional activity was evaluated as a secondary analysis. Visual function (using the VFQ 25-10) improved at 26 weeks 
in the visual search training arm (60 (SD19) to 68.4 (SD20) when compared to the Fresnel Prisms (68.5 (SD16.4) to 68.2 (18.4) 
and standard care arms ((63.7 (SD19.4) to 59.8 (SD22.7): Table 6, ANCOVA p=0.05). No evidence of differences across arms 
were found for any of the other secondary outcomes, including functional mobility (ANCOVA p=0.36, extended daily level index 
(ANCOVA p=0.93), EQ-5D VAS score (ANCOVA p=0.60), change of general health status (ANCOVA p=0.51), reading speed and 
reading accuracy. 
 
Compliance 
There were 73 protocol deviations in 58 patients (68.2% overall: 77% in the Fresnel prism arm, 93% in the visual search arm and 
34.5% in the standard care arm). The majority of deviations (n=41, 56.2%) related to lack of compliance in the intervention arms 
(e.g., prism not worn a minimum of 2 hours daily for 6 weeks or visual exercises not carried out for 30 minutes daily for 6 weeks). 
Compliance level was similar across the intervention arms. Patients in the Fresnel prisms arm wore the prisms during 27 days on 
average, and patients in the visual search training arm followed the visual search exercises 28 days on average. The protocol 
deviations in the standard group (n=10) were all related to timing and attendance at follow up visits. 
Eighteen patients (69.2%) in the Fresnel prisms arm experienced a total of 42 adverse events  of which 28 were classified as 
headache (Table 7). Two patients (6.7%) in the visual search training arm experienced seven  adverse events (6 fatigue, 1 
headache). No adverse events were recorded for in the standard care arm.  
Continuation of treatment was greater in the visual search arm than in the Fresnel prisms arm. In the visual search arm, 24 of 25 
patients continued the intervention after 6 weeks, 21 of 25 after 12 weeks and 10 of 25 patients after 26 weeks. This was in 
comparison to 14 of 26 patients in the Fresnel prism arm after 6 weeks, 12 of 23 after 12 weeks and 5 of 24 patients after 26 
weeks.  
 
Discussion  
Our primary clinical outcome measure was based on formal quantitative visual field assessment. Because of the multi-centre nature 
of the trial, a variety of visual field assessment methods were used as different hospitals had access to different perimeters. For 
future phase III trials using multiple visual field assessment methods, our sample size estimation is a maximum of 269 participants 
per arm for a minimum clinically important difference of 200 degree2 of visual field area relative change. Future trials using just one 
visual field assessment method require a sample size of a maximum of 132 participants for each arm.  
The primary clinical outcome measure for this trial was relative change in visual field area from baseline to 26 weeks. A Cochrane 
systematic review of interventions for post-stroke visual field loss concluded that, generally, interventions for homonymous 
hemianopia did not result in improvement of visual field [11]. Our results similarly showed minimal non-significant change in visual 
field across all 3 arms of 5, 8 and 3.5%. We considered that a change of 15% in visual field area would be clinically significant. The 
insignificant change in visual field was expected given the deliberate recruitment of stable hemianopes to the trial. Other trials 
recruiting stable hemianopias also report no significant change to extent of visual field loss [12,24]. 
Published evidence relating to the effectiveness of interventions for post-stroke visual field loss is limited. Pollock and colleagues 
[11] concluded from their systematic review that compensatory scanning training interventions may be more beneficial than a 
placebo or control intervention at improving specific tasks. More recently, Aimola and colleagues [12] conducted a randomised 
controlled trial of visual exploration versus sham training and reported significant improvement in vision-related quality of life 
questionnaire scores following the intervention in comparison to sham training. They found no significant objective improvement 
noted in activity of daily living tasks. Our secondary clinical outcome measures included a range of questionnaires and indices to 
measure vision-related and health-related quality of life and activities of daily living. The only outcome measure to show a 
statistically significant change was vision-related quality of life (VFQ25/10).  
Pollock and colleagues [11] found insufficient evidence to reach conclusions about the effectiveness of prisms; one more recent 
trial [24] compared real versus sham prism training. Their analysis of mobility questionnaire results showed no significant different 
in real versus sham prism use. Our data showed no significant difference in motility questionnaire results. However, we noted a 
range of adverse events related to treatment which were greatest for the Fresnel prism arm (69.2%) versus the visual search 
training arm (6.7%). There were no adverse events for standard care.  
Evaluation of recruitment and consent has been conducted for this trial and published previously [23]. We experienced greater 
recovery for hemianopia than previously reported in the literature and this should be taken into consideration when planning future 
trials with options to increase number of participating recruitment centres.  
Adverse events reported with Fresnel prism therapy included headaches, difficulties with navigation, double vision, optical 
glare/aberrations and visual confusion, similar to events reported in previous trials [14,24]. Headaches were the most common 
adverse event for Fresnel prisms. We acknowledge that headaches can also be a post-stroke symptom. However, in this trial, given 
that headaches were not a symptom reported by patients receiving standard care and uncommon in those receiving visual search 
training, they were attributed to the Fresnel prism treatment. Given the extent and range of adverse events reported with prism 
wear, caution must be exercised if prescribing prism glasses as an intervention for homonymous hemianopia.  
Adverse events for visual search training were minimal and consisted of fatigue and headache. To help minimise these potential 
side effects training periods should be curtailed to shorter accumulated periods rather than one long training session. 
We used treatment diaries to capture patient use of interventions and extracted data from these and the case report forms as to 
whether patients voluntarily chose to continue their intervention beyond the minimum set treatment period of 6 weeks. More 
patients in the visual search arm voluntarily opted to continue their intervention than patients in the Fresnel prism arm. 
We noted 73 protocol deviations. For the intervention arms, these largely related to compliance with the treatment duration 
although no significant difference was found in the level of compliance in both intervention arms. In future trials participants could  
be encouraged to break up their treatment duration per day as also suggested for reduction of adverse events; for example of 
having 3 shorter blocks of treatment per day instead of only one large block of treatment. For standard care most deviations related 
to follow-up visits taking place outside the time windows stipulated by the protocol. When planning future trials consideration should 
be given to regular telephone contact with patients to encourage on-going compliance with treatment and with timely reminders of 
upcoming review visits. This may also help with reducing loss to follow-up cases. 
 
Considerations 
A potential limitation of the trial was the need to use different visual field perimeters, and perimetrists, across recruitment sites for 
the primary outcome visual field measurements. A consideration in future trials would be to use just one perimeter type or consider 
alternative primary outcome measures. Given that visual fields did not change significantly and requires patients to attend follow-up 
appointments at hospital eye clinics (a potential deterrent to trial participation) an appropriate alternative primary outcome measure 
may be a vision-related quality of life questionnaire such as the VFQ25 although there are many other questionnaires to choose 
from dependent on whether a health-related or condition-specific questionnaire is required [25].  
With regard to generalizability, as this is a pilot trial, results should be interpreted with caution [26]. Although we found a statistically 
significant improvement in VFQ25 for visual search training, our trial was not powered for this. Nonetheless, the clinical differences 
are encouraging and warrant further investigation.  
There remains insufficient evidence to reach conclusions about whether prisms are an effective intervention, and this study 
provides evidence of a high rate of adverse events associated with prism use. Clinicians with expert knowledge relating to prisms 
may consider their use for individual patients, but clinicians and patients both should be fully aware of potential adverse events and 
have a clear understanding relating to prism use. 
 
Conclusions 
Our visual search training or Fresnel prism interventions for hemianopia produced minimal change in visual field area over the 26-
week follow-up period. Visual search training produced a significant improvement in vision-related quality of life but not for other 
activity of daily living tasks. There were no significant improvements for any quality of life measure in our Fresnel prism arm. For the 
visual search arm, our participants reported a low percentage of adverse events, many continued with training and we found a 
significant change in quality of life. This must be interpreted with caution given our low sample size  
There are a number of considerations in relation to planning future trials. Assessing change in visual field which required formal 
visual field assessment using a variety of perimeter types. It would help to limit assessment to one method or alternatively remove 
this as an outcome measure. We experienced low recruitment initially but took measures to improve this with increased number of 
recruitment centres and met the revised target for recruitment.  
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Figure 1. Cumulative recruitment graph for all centres 
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Figure 2. CONSORT 2010 Flow Diagram 
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*Complete withdrawal: patients withdrawn from all data analysis and follow up 
# Partial withdrawal: patients withdrawn from follow up 
Follow-Up 
Complete 
withdrawal* (n=1) 
Partial withdrawal# 
(n=3) 
Loss to follow up 
(n=4) 
 
Analysed  (n=22) Analysed (n=24) 
Analysis 
Complete 
withdrawal* (n=1) 
Partial withdrawal# 
(n=1) 
Loss to follow up 
(n=1) 
 
Allocated to Fresnel 
prisms (n=27) 
 
 Received allocated 
intervention 
(n=27) 
 
Allocation 
Allocated to visual 
search training 
(n=30) 
 Received allocated 
intervention 
(n=30) 
 
Allocated to standard 
care (n=30) 
 
 Received allocated 
intervention 
(n=30) 
 
Complete 
withdrawal* (n=0) 
Partial withdrawal# 
(n=5) 
Loss to follow up 
(n=0) 
 
Analysed  (n=25) 
 
Enrolment Assessed for eligibility 
(n=1171) 
Excluded  (n=1084) 
   Not meeting inclusion criteria 
(n=993) 
   Declined to participate (n=91) 
   Not randomised for other reason 
(n=0) 
Randomised (n=87) 
  
Table 1. Baseline demographic characteristics 
 
 
 
 Treatment  
Baseline Characteristic Fresnel 
prisms 
Visual 
search 
training 
Standard 
care 
Total 
Patients Randomised 26 30 29 85 
Age (years) 
Mean (SD), median (IQR), 
range 
 
69.9  (12.9) 
68.8 (14.4) 
35.2 to 
90.2 
 
70.9  
(11.2) 
72.9 (15.2) 
40.5 to 
89.3 
 
66.2  
(11.3) 
68.2 (16.2) 
42.8 to 
85.6 
 
69.0  (11.8) 
69.0 (15.3) 
36.2 to 90.2 
Gender,  
        Male, n (%) 
 
22 (84.6) 
 
17 (56.7) 
 
20 (69.0) 
 
59 (69.4) 
Ethnicity   
        White n, (%) 
        Black n, (%) 
        Asian n, (%) 
        Mixed n, (%) 
 
25 (96.1)  
1 (3.9)  
0 (0.0)   
0 (0.0)  
 
30 (100.0)  
0 (0.0)  
0 (0.0)   
0 (0.0)  
 
28 (96.6)  
1 (3.4)  
0 (0.0)   
0 (0.0)  
 
83 (97.6)  
2 (2.4)  
0 (0.0)   
0 (0.0)  
 
 
 
Table 2. Baseline clinical characteristics 
 
 Treatment  
Baseline Characteristic Fresnel prisms Visual search 
training 
Standard 
care 
Total 
Patients Randomised 26 30 29 85 
Stroke onset (days from stroke to randomisation)  
Mean (SD) 
Median (IQR) 
Range 
 
75.5  (45.3) 
64.5 (78.0) 
18.00 to 173.0 
 
73.8  (49.2) 
69.0 (97.0) 
13.0 to 172.0 
 
81.2  (48.0) 
67.0 (61.0) 
15.0 to 186.0 
 
76.9  (47.2) 
67.0 (77.0) 
13.0 to 186.0 
Stroke Type  
Ischaemic, n (%) 
Haemorrhagic, n (%) 
 
25 (96.2)  
1 (3.8)  
 
28 (93.3)  
2 (6.7)  
 
28 (96.6)  
1 (3.4)  
 
81 (95.3)  
4 (4.7)  
Side of infarct  
Left, n (%) 
Right, n (%) 
Bilateral, n (%) 
 
9 (34.6)  
16 (61.5)   
1 (3.9) 
 
17 (56.7)  
13 (43.3)   
0 (0.0) 
 
11 (37.9)  
17 (58.6)   
1 (3.5) 
 
37 (43.5)  
46 (54.1)   
2 (2.4) 
Visual field assessment diagnosis: 
 Homonymous hemianopia left partial, n (%) 
 Homonymous hemianopia right partial, n (%) 
 Homonymous hemianopia left complete, n (%) 
 Homonymous hemianopia right complete, n (%) 
 Bilateral hemianopia, n (%) 
 
8 (30.8)  
3 (11.5)   
9 (34.6)  
6 (23.1)   
0 (0.0) 
 
5 (16.7)  
9 (30.0)   
8 (26.7)  
8 (26.7)   
0 (0.0) 
 
8 (27.6)  
5 (17.2)   
10 (34.5)  
6 (20.7)   
0 (0.0) 
 
21 (24.7)  
17 (20.0)   
27 (31.8)  
20 (23.5)   
0 (0.0) 
Barthel index score 
Mean (SD) 
Median (IQR) 
Range  
 
97.5  (5.5) 
100.0 (0.0) 
80.0 to 100.0 
 
92.7  (11.9) 
100.0 (15.0) 
65.0 to 100.0 
 
93.3  (14.7) 
100.0 (5.0) 
45.0 to 100.0 
 
94.4  (11.6) 
100.0 (5.0) 
45.0 to 100.0 
 
 
 
 
  
  
 
Table 3. Sample size estimation – total number of patients with complete follow up required per arm (significance level= 
0.05) 
 
  Type II error (β) 
  0.1 0.2 0.5 
Estimated using data from  all visual field assessment methods 
Minimally clinically 
important difference 
200 degrees2 269 203 98 
400 degrees2 68 51 25 
600 degrees2 30 23 11 
Estimated using data from  modal visual field assessment method: Humphrey 
Minimally clinically 
important difference 
200 degrees2 132 100 48 
400 degrees2 33 25 12 
600 degrees2 15 12 6 
  
Table 4. Descriptive statistics for visual field by group, time-point and assessment method  
 
A: Baseline Treatment  
Timepoint 
Perimetry method (degrees2) 
Statistic 
Fresnel prisms 
 
(N=26) 
Visual search training 
(N=30) 
Standard care 
 
(N=29) 
Total 
 
(N=85) 
Baseline 
Confrontation 
n 
mean (sd) 
missing 
Humphrey Static Esterman 
n 
mean (sd) 
missing 
Goldmann Kinetic Esterman 
n 
mean (sd) 
missing 
Octopus Static Esterman 
n 
mean (sd) 
missing 
Octopus Kinetic Esterman 
n 
mean (sd) 
missing 
Other 
n 
Not done 
N 
 
 
0 
NA 
NA 
 
13 
1382.5  (1190.3) 
 0 
 
2 
779.5  (1102.4) 
0 
 
11 
1858.5  (1547.8) 
0 
 
0 
NA 
NA 
 
0 
 
0 
 
 
1 
0.0  (NA) 
0 
 
14 
1428.9  (942.1) 
0 
 
5 
922.4  (1600.4) 
0 
 
9 
1525.4  (1169.9) 
0 
 
0 
NA 
NA 
 
1 
 
0 
 
 
0 
NA 
NA 
 
12 
955.8  (840.8) 
0 
 
4 
894.3  (1541.9) 
0 
 
13 
2199.7  (1504.8) 
0 
 
0 
NA 
NA 
 
0 
 
0 
 
 
1 
0.0  (NA) 
0 
 
39 
1267.9  (1000.3) 
0 
 
11 
886.2  (1364.7) 
0 
 
33 
1902.1  (1419.9) 
0 
 
0 
NA 
NA 
 
1 
 
0 
 
  
 
B: 26 week follow up 
assessment 
Confrontation 
n 
mean (sd) 
missing 
Humphrey Static Esterman 
n 
mean (sd) 
missing 
Goldmann Kinetic Esterman 
n 
mean (sd) 
missing 
Octopus Static Esterman 
n 
mean (sd) 
missing 
Octopus Kinetic Esterman 
n 
mean (sd) 
missing 
Not done 
n 
 
 
 
0 
NA 
NA 
 
13 
1743.5  (1419.6) 
0 
 
2 
1153.5  (686.6) 
0 
 
9 
1738.4  (1498.2) 
0 
 
0 
NA 
NA 
 
2 
 
 
 
1 
3126.0  (NA) 
0 
 
11 
1542.2  (778.9) 
0 
 
5 
1792.4  (1940.3) 
0 
 
8 
1897.6  (1527.3) 
0 
 
0 
NA 
NA  
 
5 
 
 
 
0 
NA 
NA 
 
10 
1165.8  (958.6) 
0 
 
2 
1736.5  (2160.2) 
0 
 
10 
2101.3  (1514.0) 
0 
 
0 
NA 
NA 
 
5 
 
 
 
1 
3126.0  (NA) 
0 
 
34 
1508.5  (1104.5) 
0 
 
9 
1638.0  (1612.7) 
0 
 
27 
1920.6  (1461.6) 
0 
 
0 
NA 
NA 
 
14 
 
0 represents complete homonymous hemianopia 
6262 is the maximum visual field area score representing a normal hemifield 
  
  
Table 5. Relative change in visual field  
 
A: by treatment group  
     95% Confidence Interval for 
Mean 
 N Mean Std. 
Deviation 
Std. Error Lower 
bound 
Upper bound 
Fresnel prisms 24 0.05247973 0.13958788 0.02849326 -0.00646 0.11142 
Visual search training 24 0.08152371 0.14880363 0.03037441 0.01869 0.14436 
Standard care 22 0.0352049 0.15023043 0.03202924 -0.03140 0.10181 
Total 70 0.0570084 0.1453011 0.0173668 0.02236 0.09165 
 
 
B:  ANOVA results for relative change in visual field (comparison across arms) 
 
Source Sum of squares DF Mean 
Square 
F-test P-
value 
Treatment 0.02537506 2 0.01268753 0.59 0.5551 
Error 1.43138058 67 0.02136389   
Corrected total 1.45675564 69    
 
 
  
  
Table 6 VFQ outcome assessment 
 
A: Descriptive statistics by group and time-point 
 
 Treatment  
Timepoint 
     Statistic 
Fresnel prisms 
 
(26) 
Visual search training 
(N=30) 
Standard care 
 
(N=29) 
Total 
 
(N=85) 
Baseline 
n 
mean (sd) 
median (IQR) 
(min, max) 
Not done 
 
25 
68.5  (16.4) 
71.2 (62.1 to 76.9) 
(19.8, 93.9) 
1 
 
 
30 
60.0  (19.0) 
56.4 (44.5 to 78.8) 
(21.2, 96.0) 
0 
 
28 
63.7  (19.4) 
63.2 (44.6 to 77.2) 
(35.0, 93.0) 
1 
 
 
83 
63.8  (18.5) 
64.4 (47.0 to 77.7) 
(19.8, 96.0) 
2 
 
26 follow-up assessment 
n 
mean (sd) 
median (IQR) 
(min, max) 
Not done 
 
24 
68.2  (18.4) 
70.1 (57.1 to 84.7) 
(18.2, 96.5) 
2 
 
 
25 
68.4  (20.0) 
73.4 (53.5 to 83.0) 
(25.5, 99.2) 
5 
 
19 
59.8  (22.7) 
63.9 (38.2 to 79.4) 
(22.9, 95.2) 
10 
 
 
68 
65.9  (20.3) 
68.9 (53.2 to 85.6)) 
(18.2, 99.2) 
17 
 
 
B: Analysis of Covariance (ANCOVA) results for changes in VFQ scores across arms  
 
Patients who do not have VFQ data for baseline and/or 26 week follow up were not included  
 
Source Sum of squares DF Mean Square F-test P-value 
Baseline score 13368.70569 1 13368.70569 65.05 <0.0001 
Treatment 1294.77789 2 647.38895 3.15 0.0497 
Error 12947.44855 63 205.51506   
Corrected total 27610.93214 66    
  
 
Parameter Estimates 
 
Variable Estimate Standard 
Error 
t-value P-value 
Intercept 10.0277624
6 
6.92848157 1.45 0.1528 
Baseline score 0.80599816 0.09875501 8.16 <0.0001 
Visual Search 
Training 
10.4170670
4 
4.36870996 2.38 0.0201 
Fresnel Prism 2.86798670 4.49330209 0.64 0.5256 
Standard Care 0.00000000 . . . 
 
  
  
Table 7. Adverse events across groups  
 
Adverse event Fresnel prisms 
 
(N=26) 
Visual search training 
(N=30) 
Standard care 
 
(N=29) 
Event  Events: n Patients: n(%) Events: n Patients: n(%) Events: n Patients: n(%) 
Difficulty with navigation 2 2 (7.7) 0 0 (0.0) 0 0 (0.0) 
Diplopia 5 5 (19.2) 0 0 (0.0) 0 0 (0.0) 
Dizziness 2 1 (3.8) 0 0 (0.0) 0 0 (0.0) 
Fatigue 0 0 (0.0) 6 1 (3.3) 0 0 (0.0) 
Headache 28 6 (23.1) 1 1 (3.3) 0 0 (0.0) 
Optical glare/aberrations 1 1 (3.8) 0 0 (0.0) 0 0 (0.0) 
Visual confusion 4 3 (11.5) 0 0 (0.0) 0 0 (0.0) 
Total 42 18 (69.2) 7 2 (6.7) 0 0 (0.0) 
 
 
 
 
 
